<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03139279</url>
  </required_header>
  <id_info>
    <org_study_id>IRB: 932304</org_study_id>
    <nct_id>NCT03139279</nct_id>
  </id_info>
  <brief_title>Propofol and Dexmedetomidine Versus a Propofol Only Regimen for Sedation During Colonoscopy</brief_title>
  <official_title>Comparing Time to Readiness for Discharge After Colonoscopy: Propofol and Dexmedetomidine vs Propofol Only Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Downstate Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York - Downstate Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An ideal sedative for colonoscopy should have properties that include: rapid onset and offset
      of action, provide cardiopulmonary stability, have minimal adverse effects, and allow for
      smooth recovery, and early discharge. Propofol is often used solely because of its rapid
      onset and short duration of action---a property which is ideal for a fast recovery and early
      discharge in the ambulatory setting. However, the use of propofol has been associated with
      undesirable effects such as hypotension, hypoventilation and apnea requiring assisted
      ventilation.

      Balanced anesthesia, using a combination of medications with different mechanisms of action
      can reduce the total amount of each sedative agent used and minimize their side effects while
      achieving the desired level of sedation. Dexmedetomidine is one agent that has been used
      either alone or in combination with propofol for sedation during colonoscopy. While there are
      many advantages to using dexmedetomidine, there is concern that the use of this agent for
      sedation during colonoscopy may prolong post-operative recovery time and readiness for
      discharge home.

      No study has definitively assessed whether the use of dexmedetomidine in combination with
      propofol during ambulatory colonoscopy prolongs post-operative recovery time as determined by
      the Modified Post Anesthesia Discharge Scoring System (MPADSS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, investigators plan to prospectively compare in a randomized, controlled,
      double-blind trial, the sedation technique for colonoscopy between two groups. Group 1:
      sedation with dexmedetomidine and propopfol versus group 2: sedation with saline placebo and
      propofol.

      The study will have the following outcome measures for each group.

      Primary outcome measure:

      Readiness-for-discharge (RFD) at 10, 20 and 30 minutes after the colonoscopic procedure.
      Ready-for-discharge is defined as attainment of MPADSS score of 9-10.

      Secondary outcome measures:

        1. Total propofol consumption in mg/kg/duration of procedure in minutes;

        2. Side effects:

             1. lowest intraoperative percent (%) drop in mean arterial pressure (MAP) from
                baseline,

             2. incidence of sustained bradycardic episodes (HR&lt;50 for at least 5 minutes)
                intraoperatively,

             3. incidence of apneic episodes intraoperatively requiring positive pressure
                ventilation.

      Methods:

      One hundred patients will be recruited and randomized into two groups. For sedation, Group 1
      will receive intravenous dexmedetomidine 0.3 ug/kg bolused at the onset of the procedure
      followed by titrated doses of propofol. Group 2 will receive a saline placebo bolus at the
      onset of the procedure followed by titrated doses of propofol. A hospital research
      pharmacist, based on a randomization table, will allocate to the anesthesia provider giving
      the sedation, the bolus syringe labelled dexmedetomidine/or saline study agent. The
      anesthesia provider, gastroenterologist, nurses as well as the subject will be blinded as to
      the syringe's actual content. A Bispectral Index (BIS) Monitor will be used during sedation.
      All subjects will be targeted to maintain a BIS score between 60-70. Outcome measures will be
      evaluated for statistical significance in a non-inferiority assessment.

      Investigators hypothesize that there will be no difference in the time to discharge between
      the two treatment groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Actual">July 19, 2018</completion_date>
  <primary_completion_date type="Actual">May 4, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Ready for Discharge in Each Group at 30 Minutes Post Procedure</measure>
    <time_frame>30 minutes</time_frame>
    <description>Each subject was assessed for readiness for discharge at 10, 20 and 30 minutes after the procedure, using the Modified Post-Anesthesia Discharge Scoring System (MPADSS). A subject getting an MPADS score of 9-10 is deemed ready for discharge. The percentage of subjects ready for discharge in each group at 10, 20 and 30 minutes will be measured as primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Total Propofol Consumption Per Group</measure>
    <time_frame>between 7 and 57 minutes (median 19 min)</time_frame>
    <description>Total propofol consumption per subject was measured as μg/kg/min of procedure in minutes. The average propofol consumption in each group will be measured as secondary outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sustained Bradycardic Episodes</measure>
    <time_frame>30 minutes</time_frame>
    <description>Incidence of sustained bradycardic episodes (HR&lt;50 for at least 5 minutes) intraoperatively in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest Intraoperative % Change in MAP From Baseline</measure>
    <time_frame>30 minutes</time_frame>
    <description>Lowest intraoperative percent (%) change in mean arterial pressure (MAP) from baseline (average in each group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Apneic Episodes Intraoperatively Requiring Positive Pressure Ventilation</measure>
    <time_frame>30 minutes</time_frame>
    <description>Incidence of apneic episodes intraoperatively requiring positive pressure ventilation in each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine and propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo and propofol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine 0.3 ug/kg intravenous bolus</description>
    <arm_group_label>Dexmedetomidine and propofol</arm_group_label>
    <other_name>Dex</other_name>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>Intravenous saline/placebo</description>
    <arm_group_label>Saline placebo and propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol titrated intravenous boluses</description>
    <arm_group_label>Dexmedetomidine and propofol</arm_group_label>
    <arm_group_label>Saline placebo and propofol</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • patients scheduled to undergo colonoscopy at SUNY Downstate Medical Center.

        Exclusion Criteria:

          -  &lt; 18 years old

          -  &gt; 75 years old

          -  Cognitively Impaired patients (Cognitively impaired patients are excluded from the
             study because our primary outcome involves a very strict discharge criteria that
             requires the patient to respond to and perform tasks on our pre-existing discharge
             scale checklist. These may be impossible to assess or will be difficult to standardize
             for patients whom are Cognitively Impaired.)

          -  Pregnant patients

          -  Patients who use a wheelchair or ambulates with crutches (Patients using a wheelchair
             are excluded from the study because our primary outcome involves a very strict
             discharge criteria that requires the patient to respond to and perform tasks on our
             pre-existing discharge scale checklist. These may be impossible to assess or will be
             difficult to standardize for patients whom who use a wheel-chair).

          -  Limited exercise tolerance (as this could represent active coronary disease)

          -  Total body weight greater than 105 kg (due to maximal dose of drug available in
             randomized syringes containing study drug)

          -  Propofol, soy, glycerol or dexmedetomidine allergy

          -  Significant renal impairment

          -  Significant hepatic impairment

          -  Inability to read or write in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Dimaculangan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY Downstate Medical Center Department of Anesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vicari JJ. Sedation and analgesia. Gastrointest Endosc Clin N Am. 2002 Apr;12(2):297-311, viii. Review.</citation>
    <PMID>12180162</PMID>
  </reference>
  <reference>
    <citation>Faigel DO, Baron TH, Goldstein JL, Hirota WK, Jacobson BC, Johanson JF, Leighton JA, Mallery JS, Peterson KA, Waring JP, Fanelli RD, Wheeler-Harbaugh J; Standards Practice Committe, American Society for Gastrointestinal Endoscopy. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc. 2002 Nov;56(5):613-7.</citation>
    <PMID>12397263</PMID>
  </reference>
  <reference>
    <citation>Waring JP, Baron TH, Hirota WK, Goldstein JL, Jacobson BC, Leighton JA, Mallery JS, Faigel DO; American Society for Gastrointestinal Endoscopy, Standards of Practice Committee. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. Gastrointest Endosc. 2003 Sep;58(3):317-22. Review.</citation>
    <PMID>14528201</PMID>
  </reference>
  <reference>
    <citation>Akarsu Ayazoğlu T, Polat E, Bolat C, Yasar NF, Duman U, Akbulut S, Yol S. Comparison of propofol-based sedation regimens administered during colonoscopy. Rev Med Chil. 2013 Apr;141(4):477-85. doi: 10.4067/S0034-98872013000400009.</citation>
    <PMID>23900369</PMID>
  </reference>
  <reference>
    <citation>Tuncali B, Pekcan YO, Celebi A, Zeyneloglu P. Addition of low-dose ketamine to midazolam-fentanyl-propofol-based sedation for colonoscopy: a randomized, double-blind, controlled trial. J Clin Anesth. 2015 Jun;27(4):301-6. doi: 10.1016/j.jclinane.2015.03.017. Epub 2015 Mar 20.</citation>
    <PMID>25801162</PMID>
  </reference>
  <reference>
    <citation>Kamibayashi T, Maze M. Clinical uses of alpha2 -adrenergic agonists. Anesthesiology. 2000 Nov;93(5):1345-9. Review.</citation>
    <PMID>11046225</PMID>
  </reference>
  <reference>
    <citation>Taittonen MT, Kirvelä OA, Aantaa R, Kanto JH. Effect of clonidine and dexmedetomidine premedication on perioperative oxygen consumption and haemodynamic state. Br J Anaesth. 1997 Apr;78(4):400-6.</citation>
    <PMID>9135361</PMID>
  </reference>
  <reference>
    <citation>Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg. 2002 Aug;95(2):461-6, table of contents.</citation>
    <PMID>12145072</PMID>
  </reference>
  <reference>
    <citation>Jalowiecki P, Rudner R, Gonciarz M, Kawecki P, Petelenz M, Dziurdzik P. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology. 2005 Aug;103(2):269-73.</citation>
    <PMID>16052108</PMID>
  </reference>
  <reference>
    <citation>Dere K, Sucullu I, Budak ET, Yeyen S, Filiz AI, Ozkan S, Dagli G. A comparison of dexmedetomidine versus midazolam for sedation, pain and hemodynamic control, during colonoscopy under conscious sedation. Eur J Anaesthesiol. 2010 Jul;27(7):648-52. doi: 10.1097/EJA.0b013e3283347bfe.</citation>
    <PMID>20531094</PMID>
  </reference>
  <reference>
    <citation>Palumbo P, Tellan G, Perotti B, Pacilè MA, Vietri F, Illuminati G. Modified PADSS (Post Anaesthetic Discharge Scoring System) for monitoring outpatients discharge. Ann Ital Chir. 2013 Nov-Dec;84(6):661-5.</citation>
    <PMID>23165318</PMID>
  </reference>
  <reference>
    <citation>Aldrete JA, Kroulik D. A postanesthetic recovery score. Anesth Analg. 1970 Nov-Dec;49(6):924-34.</citation>
    <PMID>5534693</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <results_first_submitted>April 12, 2019</results_first_submitted>
  <results_first_submitted_qc>June 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2019</results_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Downstate Medical Center</investigator_affiliation>
    <investigator_full_name>Dennis Dimaculangan</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03139279/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>We consented 122 patients of which 8 were immediately excluded for the following reasons: procedure began prior to randomization (3), inclusion criteria not met (3), anesthesiologist declined (1), patient withdrew consent (1); 114 were randomized into the treatment and placebo groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine and Propofol</title>
          <description>Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Dexmedetomidine: Dexmedetomidine 0.3 ug/kg intravenous bolus
Propofol: Propofol titrated intravenous boluses</description>
        </group>
        <group group_id="P2">
          <title>Saline Placebo and Propofol</title>
          <description>Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Saline placebo: Intravenous saline/placebo
Propofol: Propofol titrated intravenous boluses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>114 were randomized into the treatment and placebo groups. Seven additional patients in the propofol-dexmedetomidine group and 6 in the propofol-saline group were excluded. Final n = 101</population>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine and Propofol</title>
          <description>Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Dexmedetomidine: Dexmedetomidine 0.3 ug/kg intravenous bolus
Propofol: Propofol titrated intravenous boluses</description>
        </group>
        <group group_id="B2">
          <title>Saline Placebo and Propofol</title>
          <description>Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Saline placebo: Intravenous saline/placebo
Propofol: Propofol titrated intravenous boluses</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age measured in years</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="52" upper_limit="61"/>
                    <measurement group_id="B2" value="56" lower_limit="48.8" upper_limit="65"/>
                    <measurement group_id="B3" value="56" lower_limit="50" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" lower_limit="66" upper_limit="88.2"/>
                    <measurement group_id="B2" value="83.5" lower_limit="69.1" upper_limit="93.4"/>
                    <measurement group_id="B3" value="80" lower_limit="69.85" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>inches</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="64" upper_limit="67"/>
                    <measurement group_id="B2" value="65" lower_limit="64" upper_limit="68"/>
                    <measurement group_id="B3" value="65" lower_limit="64" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" lower_limit="23.7" upper_limit="30.9"/>
                    <measurement group_id="B2" value="28.5" lower_limit="24.6" upper_limit="32.8"/>
                    <measurement group_id="B3" value="28.31" lower_limit="24.58" upper_limit="31.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ASA Physical Status Classification System</title>
          <description>The American Society of Anesthesiologists (ASA) physical status (ASAPS) classification system was developed to offer clinicians a simple categorization of a patient’s physiological status that can be helpful in predicting operative risk. Developed By: ASA House of Delegates/Executive Committee. Last Amended: October 15, 2014 (original approval: October 15, 2014). Includes 4 categories: ASA I, II, III, IV, V, VI. The addition of “E” to the ASAPS (e.g., ASA 2E) denotes an emergency surgical procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ASA I: A normal healthy patient</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASA II: A patient with mild systemic disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASA III: A patient with severe systemic disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASA IV: systemic disease, constant threat to life</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASA V: moribund pt, will not survive w/o operation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASA VI: declared brain-dead patient</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134" lower_limit="125" upper_limit="144.5"/>
                    <measurement group_id="B2" value="140.5" lower_limit="122.2" upper_limit="147.7"/>
                    <measurement group_id="B3" value="135" lower_limit="124" upper_limit="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82" lower_limit="75" upper_limit="90.5"/>
                    <measurement group_id="B2" value="81" lower_limit="73" upper_limit="90.75"/>
                    <measurement group_id="B3" value="81" lower_limit="74" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Arterial Pressure</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99" lower_limit="94" upper_limit="111"/>
                    <measurement group_id="B2" value="99" lower_limit="91" upper_limit="111"/>
                    <measurement group_id="B3" value="99" lower_limit="92" upper_limit="110.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <units>beats per minute</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="61.5" upper_limit="78"/>
                    <measurement group_id="B2" value="71" lower_limit="62.5" upper_limit="81"/>
                    <measurement group_id="B3" value="71" lower_limit="62" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Ready for Discharge in Each Group at 30 Minutes Post Procedure</title>
        <description>Each subject was assessed for readiness for discharge at 10, 20 and 30 minutes after the procedure, using the Modified Post-Anesthesia Discharge Scoring System (MPADSS). A subject getting an MPADS score of 9-10 is deemed ready for discharge. The percentage of subjects ready for discharge in each group at 10, 20 and 30 minutes will be measured as primary outcome.</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine and Propofol</title>
            <description>Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Dexmedetomidine: Dexmedetomidine 0.3 ug/kg intravenous bolus
Propofol: Propofol titrated intravenous boluses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo and Propofol</title>
            <description>Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Saline placebo: Intravenous saline/placebo
Propofol: Propofol titrated intravenous boluses</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Ready for Discharge in Each Group at 30 Minutes Post Procedure</title>
          <description>Each subject was assessed for readiness for discharge at 10, 20 and 30 minutes after the procedure, using the Modified Post-Anesthesia Discharge Scoring System (MPADSS). A subject getting an MPADS score of 9-10 is deemed ready for discharge. The percentage of subjects ready for discharge in each group at 10, 20 and 30 minutes will be measured as primary outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Total Propofol Consumption Per Group</title>
        <description>Total propofol consumption per subject was measured as μg/kg/min of procedure in minutes. The average propofol consumption in each group will be measured as secondary outcome.</description>
        <time_frame>between 7 and 57 minutes (median 19 min)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine and Propofol</title>
            <description>Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Dexmedetomidine: Dexmedetomidine 0.3 ug/kg intravenous bolus
Propofol: Propofol titrated intravenous boluses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo and Propofol</title>
            <description>Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Saline placebo: Intravenous saline/placebo
Propofol: Propofol titrated intravenous boluses</description>
          </group>
        </group_list>
        <measure>
          <title>Average Total Propofol Consumption Per Group</title>
          <description>Total propofol consumption per subject was measured as μg/kg/min of procedure in minutes. The average propofol consumption in each group will be measured as secondary outcome.</description>
          <units>μg/kg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" lower_limit="120" upper_limit="200"/>
                    <measurement group_id="O2" value="180" lower_limit="130" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sustained Bradycardic Episodes</title>
        <description>Incidence of sustained bradycardic episodes (HR&lt;50 for at least 5 minutes) intraoperatively in each group</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine and Propofol</title>
            <description>Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Dexmedetomidine: Dexmedetomidine 0.3 ug/kg intravenous bolus
Propofol: Propofol titrated intravenous boluses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo and Propofol</title>
            <description>Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Saline placebo: Intravenous saline/placebo
Propofol: Propofol titrated intravenous boluses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Bradycardic Episodes</title>
          <description>Incidence of sustained bradycardic episodes (HR&lt;50 for at least 5 minutes) intraoperatively in each group</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Sustained bradycardia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No sustained bradycardia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lowest Intraoperative % Change in MAP From Baseline</title>
        <description>Lowest intraoperative percent (%) change in mean arterial pressure (MAP) from baseline (average in each group)</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine and Propofol</title>
            <description>Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Dexmedetomidine: Dexmedetomidine 0.3 ug/kg intravenous bolus
Propofol: Propofol titrated intravenous boluses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo and Propofol</title>
            <description>Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Saline placebo: Intravenous saline/placebo
Propofol: Propofol titrated intravenous boluses</description>
          </group>
        </group_list>
        <measure>
          <title>Lowest Intraoperative % Change in MAP From Baseline</title>
          <description>Lowest intraoperative percent (%) change in mean arterial pressure (MAP) from baseline (average in each group)</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="25" upper_limit="38"/>
                    <measurement group_id="O2" value="21" lower_limit="14" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Apneic Episodes Intraoperatively Requiring Positive Pressure Ventilation</title>
        <description>Incidence of apneic episodes intraoperatively requiring positive pressure ventilation in each group</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine and Propofol</title>
            <description>Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Dexmedetomidine: Dexmedetomidine 0.3 ug/kg intravenous bolus
Propofol: Propofol titrated intravenous boluses</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo and Propofol</title>
            <description>Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Saline placebo: Intravenous saline/placebo
Propofol: Propofol titrated intravenous boluses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Apneic Episodes Intraoperatively Requiring Positive Pressure Ventilation</title>
          <description>Incidence of apneic episodes intraoperatively requiring positive pressure ventilation in each group</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From patient enrollment through discharge from PACU</time_frame>
      <desc>The definition of adverse event, used to collect adverse event information in the study, did not differ from the clinicaltrials.gov.
Additional information: list of potential adverse events relevant to the study included:
episodes of sustained bradycardia (greater than 5 minutes) associated with hypotension (MAP &lt; 60 mm Hg) that were unresponsive to treatment. We used a cutoff of &lt; 50 bpm to define bradycardia in this study.
apnea requiring positive pressure ventilation</desc>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine and Propofol</title>
          <description>Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Dexmedetomidine: Dexmedetomidine 0.3 ug/kg intravenous bolus
Propofol: Propofol titrated intravenous boluses</description>
        </group>
        <group group_id="E2">
          <title>Saline Placebo and Propofol</title>
          <description>Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
Saline placebo: Intravenous saline/placebo
Propofol: Propofol titrated intravenous boluses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dennis Dimaculangan, MD</name_or_title>
      <organization>Department of Anesthesiology, SUNY Downstate Medical Center</organization>
      <phone>718-270-3765</phone>
      <email>dennis.dimaculangan@downstate.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

